SEC Form 4 · accession 0000914190-19-000065

REGENERX BIOPHARMACEUTICALS INC · RGRX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Feb 27, 2019

Accepted (ET)

Mar 1, 2019 · 4:47 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000707511

Table I — non-derivative securities

No Table I lines on this filing.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Convertible Promissory Note (right to buy)	$0.12	Feb 27, 2019	P	—	A	Feb 27, 2019	Feb 27, 2024	Common Stock	41,667	—	D
Common Stock Warrant (right to buy)	$0.18	Feb 27, 2019	P	31,250	A	Aug 27, 2019	Feb 27, 2024	Common Stock	31,250	31,250	D
Stock Option (right to buy)^F1	$0.16	holding	—	—	—	—	Apr 3, 2019	Common Stock	50,000	50,000	D
Stock Option (right to buy)^F1	$0.57	holding	—	—	—	—	Apr 10, 2019	Common Stock	7,155	7,155	D
Stock Option (right to buy)^F1	$0.21	holding	—	—	—	—	Mar 25, 2021	Common Stock	150,000	150,000	D
Stock Option (right to buy)^F1	$0.19	holding	—	—	—	—	Feb 11, 2022	Common Stock	100,000	100,000	D
Stock Option (right to buy)^F1	$0.36	holding	—	—	—	—	Jun 30, 2022	Common Stock	100,000	100,000	D
Stock Option (right to buy)^F2	$0.64	holding	—	—	—	—	Mar 16, 2023	Common Stock	100,000	100,000	D
Stock Option (right to buy)^F3	$0.28	holding	—	—	—	—	Sep 1, 2027	Common Stock	125,000	125,000	D
Stock Option (right to buy)^F4	$0.21	holding	—	—	—	—	Jul 17, 2028	Common Stock	200,000	200,000	D